Treatment of Parkinson's Disease with Comorbid Depression
Depression is a recognised comorbidity in Parkinson's disease and requires dedicated pharmacotherapeutic management alongside optimal dopaminergic treatment. The choice of antidepressant is not uniform — it is determined by the severity of depression and the patient's predominant symptom features.
Clinical scenario: A patient with Parkinson's disease presenting with depression. Optimal dopaminergic therapy should be in place. Antidepressant selection is then guided by the severity of the depressive episode and the specific symptom cluster — whether lethargy, agitation, anxiety, sleep disturbance, or other features predominate.
Treatment Approach
Antidepressant therapy is stratified by depression severity and symptom profile. The protocol specifies distinct agent categories for different presentations — the full structured regimen, including sequencing and agent-selection criteria, is available via the link below.
References
DOI: 10.1186/s42466-024-00325-4
- Regarding pharmacotherapy, to treat depressive disorders in PD patients, optimal dopaminergic medication should be used and a therapy with Pramipexole should be conducted if therapy with a Dopamine agonist is possible.
- Severe depression in PD patients can be treated with Venlafaxine or Desipramine.
- depression with lethargy: Venlafaxine, Citalopram, or Sertraline
- depression with agitation, anxiety, restlessness, or sleep disturbance: Mirtazapine (not if RBD is present) or Trazodone.
- depression with comorbid sleep disturbance, pain or drooling, in cognitively unimpaired patients: Amitriptyline.
View source ↗